Related Experiment Video
Updated: Oct 28, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Clinical Challenges in Triple-Negative Breast Cancer (TNBC): Current Treatment Options, Their Limitations, and
Rubismita Deka1, Thiyam Ramsing Singh1
1Department of Molecular Biology and Biotechnology, Tezpur University, Napaam, Tezpur 784028, Assam, India.
Abstract:
Triple-negative breast cancer (TNBC) is characterised by the absence of expression of oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Compared with other breast cancer subtypes, TNBC is generally associated with a more aggressive clinical course, in part because of its marked molecular heterogeneity. Consequently, the availability of effective targeted therapies remains limited. Chemotherapy continues to be a major component of treatment, although its clinical benefit may be constrained by toxicity and the development of drug resistance. This review examines the principal clinical challenges in TNBC, evaluates currently available therapeutic approaches and their limitations, and discusses important areas that remain insufficiently addressed. Particular emphasis is placed on recent advances in emerging treatment strategies. Together, these developments may improve our understanding of TNBC and support future research towards more precise and personalised therapeutic approaches.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Tumor Immunotherapy
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
